AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20513572 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 locking screws in the proximal row (Group c)
Number of subjects: 32
Study 20513572 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 locking screws filling all screw holes in the distal and proximal rows (Group d)
Number of subjects: 32
Study 17418728 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (200/0.5) solution to bring down the hematocrit to 45%
Number of subjects: 50
Study 17418728 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose solution
Number of subjects: 50
Study 15466458 — intervention group
Group type: COMPARATOR
Intervention: CMS patients
Number of subjects: 22
Study 15466458 — intervention group
Group type: EXPERIMENTAL
Intervention: HA controls
Number of subjects: 22
Study 12060503 — intervention group
Group type: EXPERIMENTAL
Intervention: Doublebase (novel hydro-gel emollient)
Number of subjects: 78
Study 10682436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 66
Study 10682436 — intervention group
Group type: COMPARATOR
Intervention: Control (surgical group)
Number of subjects: 66
Study 10682436 — intervention group
Group type: COMPARATOR
Intervention: Control (non-pregnant women)
Number of subjects: 66
Study 10682436 — intervention group
Group type: COMPARATOR
Intervention: Control (early pregnancy progression)
Number of subjects: 66
Study 7615947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8654
Study 2515215 — intervention group
Group type: EXPERIMENTAL
Intervention: Active patch (N = 11)
Number of subjects: 20
Study 2515215 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch (N = 9)
Number of subjects: 20
Study 326447 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study 326447 — intervention group
Group type: COMPARATOR
Intervention: Control (dummy preparation)
Number of subjects: 0
Study 30883284 — intervention group
Group type: EXPERIMENTAL
Intervention: Check Yourself tool + SBHC visit
Number of subjects: 148
Study 30883284 — intervention group
Group type: COMPARATOR
Intervention: SBHC visit without Check Yourself tool
Number of subjects: 148
Study 30883284 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 148
Study 29436364 — intervention group
Group type: EXPERIMENTAL
Intervention: WAVES intervention (12-month intervention promoting healthy eating and physical activity)
Number of subjects: 1467
Study 29436364 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 1467
Study 27521672 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DXI; Ozurdex) in combination with ranibizumab (Lucentis)
Number of subjects: 10
Study 27521672 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (Lucentis) alone
Number of subjects: 10
Study 24932567 — intervention group
Group type: EXPERIMENTAL
Intervention: Social facilitation maintenance (SFM)
Number of subjects: 150
Study 24932567 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral skills maintenance treatment (BSM)
Number of subjects: 150
Study 24932567 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 22011511 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 200 mg twice-daily
Number of subjects: 0
Study 22011511 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisbamate 600 mg twice-daily
Number of subjects: 0
Study 19581013 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with AT allele (GC/AT+AT/AT)
Number of subjects: 138
Study 19581013 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with GC/GC genotype
Number of subjects: 138
Study 19581013 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with GC/GC genotype, negative p53 and weak survivin expression
Number of subjects: 138
Study 19581013 — intervention group
Group type: COMPARATOR
Intervention: Non-radiotherapy group
Number of subjects: 138
Study 17180159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato-based food for special medical purposes (FSMP) consumed at 100 g/day for 6 months by HCV patients
Number of subjects: 39
Study 17180159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato-based food for special medical purposes (FSMP) consumed at 100 g/day for 1 week by healthy subjects
Number of subjects: 39
Study 17180159 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato-based food for special medical purposes (FSMP)
Number of subjects: 39
Study 17180159 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonresponder patients without FSMP)
Number of subjects: 39
Study 15530294 — intervention group
Group type: EXPERIMENTAL
Intervention: LHE plus salicylic acid
Number of subjects: 13
Study 15530294 — intervention group
Group type: COMPARATOR
Intervention: Salicylic-acid cream alone
Number of subjects: 13
Study 11797074 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nicotine
Number of subjects: 63
Study 11797074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9549664 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional formulation (CF) venlafaxine 50 mg
Number of subjects: 16
Study 9549664 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release formulation (XR) venlafaxine 75 mg
Number of subjects: 16
Study 9549664 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous venlafaxine 10 mg
Number of subjects: 16
Study 9549664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7654925 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing advice through direct interview or telephone call to non-vaccinated patients.
Number of subjects: 378
Study 7654925 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct interview back-up at the Nursing station.
Number of subjects: 378
Study 7654925 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall retrieval effectiveness of nursing intervention.
Number of subjects: 378
Study 2659953 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 2 mcg/d for 7 days, followed by 100 U/d Salmon Calcitonin + 1 g/d Calcitonin for 21 days, followed by Calcium alone for 2 months
Number of subjects: 20
Study 2659953 — intervention group
Group type: COMPARATOR
Intervention: Salmon Calcitonin alone
Number of subjects: 20
Study 2659953 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone for 1 year
Number of subjects: 20
Study 31050562 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 80
Study 31050562 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release (from day 3 to day 6 post-surgery)
Number of subjects: 80
Study 31455404 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 439
Study 27253835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Thrust
Number of subjects: 0
Study 27253835 — intervention group
Group type: EXPERIMENTAL
Intervention: Front Squat
Number of subjects: 0
Study 25510441 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic lead shielding
Number of subjects: 332
Study 23560454 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketamine (0.5 mg/kg)
Number of subjects: 114
Study 23560454 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 114
Study 22938659 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive fluid management (25-35 ml×kg(‐1)×d(‐1))
Number of subjects: 30
Study 22938659 — intervention group
Group type: COMPARATOR
Intervention: Traditional fluid management (40-50 ml×kg(‐1)×d(‐1))
Number of subjects: 30
Study 22938659 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive fluid management
Number of subjects: 30
Study 22938659 — intervention group
Group type: COMPARATOR
Intervention: Traditional fluid management
Number of subjects: 30
Study 17989993 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol-containing disinfectant
Number of subjects: 14
Study 17989993 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-propanol-containing disinfectant
Number of subjects: 14
Study 17989993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ethanol and 2-propanol disinfectants
Number of subjects: 14
Study 17472545 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 0
Study 16087989 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 286
Study 16087989 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Fat Mass
Number of subjects: 286
Study 16087989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-adjusted appendicular lean mass (aLM)
Number of subjects: 286
Study 11799501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal opioids
Number of subjects: 7
Study 11799501 — intervention group
Group type: COMPARATOR
Intervention: Epidural local anesthetics
Number of subjects: 7
Study 9892878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 4 days
Number of subjects: 165
Study 9892878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 7 days
Number of subjects: 165
Study 9892878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. plus clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. for 10 days
Number of subjects: 165
Study 7740846 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms L-thyroxine injected intraamniotically
Number of subjects: 40
Study 7740846 — intervention group
Group type: COMPARATOR
Intervention: Control group of prematures selected according to gestational age
Number of subjects: 40
Study 1723379 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 0
Study 1723379 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 micrograms inhaled twice daily
Number of subjects: 0
Study 1723379 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0
Study 1723379 — intervention group
Group type: COMPARATOR
Intervention: Regular beta 2‐agonist therapy
Number of subjects: 0
Study 6126423 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1000 mg/day
Number of subjects: 99
Study 6126423 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxmetidine 800 mg/day
Number of subjects: 99
Study 30893150 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy in the STRASS-1 study
Number of subjects: 0
Study 30893150 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy for high-grade liposarcoma and leiomyosarcoma of the retroperitoneum in the upcoming STRASS-2 study
Number of subjects: 0
Study 28278301 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 150
Study 28278301 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study 26462680 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized nasal mask cushion
Number of subjects: 40
Study 26462680 — intervention group
Group type: COMPARATOR
Intervention: Conventional nasal mask cushion
Number of subjects: 40
Study 23242490 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 20
Study 23242490 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 20
Study 21762150 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1%w/w o-cymen-5-ol/ 0.6%w/w zinc chloride dentifrice
Number of subjects: 224
Study 21762150 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride/silica control dentifrice
Number of subjects: 224
Study 19500080 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-edit film (3.5 minutes)
Number of subjects: 0
Study 19500080 — intervention group
Group type: COMPARATOR
Intervention: Slow-edit film (3.5 minutes)
Number of subjects: 0
Study 16911869 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg dry powder inhalation twice daily for 8 weeks
Number of subjects: 204
Study 16911869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 16911869 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 204
Study 15038626 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive agent therapy (AHA)
Number of subjects: 1121
Study 15038626 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification (LSM)
Number of subjects: 1121
Study 15038626 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 1121
Study 11176085 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 54
Study 11176085 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-midazolam
Number of subjects: 54
Study 11176085 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 54
Study 11176085 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 54
Study 9625400 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg, once daily at bedtime)
Number of subjects: 681
Study 9625400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 681
Study 8174730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for 3 months
Number of subjects: 239
Study 8174730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 3420170 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolfing pelvic mobilization session (45 minutes)
Number of subjects: 32
Study 3420170 — intervention group
Group type: COMPARATOR
Intervention: Control session without manipulation (45 minutes)
Number of subjects: 32
Study 30376086 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-bOPV
Number of subjects: 152
Study 30376086 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-only (IPV-IPV-IPV)
Number of subjects: 152
Study 30376086 — intervention group
Group type: COMPARATOR
Intervention: mOPV2 (challenge dose)
Number of subjects: 152
Study 28216065 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling (TC)
Number of subjects: 92
Study 28216065 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 92
Study 26333543 — intervention group
Group type: EXPERIMENTAL
Intervention: EBFR of 200 mL/min
Number of subjects: 22
Study 26333543 — intervention group
Group type: EXPERIMENTAL
Intervention: EBFR of 300 mL/min
Number of subjects: 22
Study 26333543 — intervention group
Group type: EXPERIMENTAL
Intervention: EBFR of 200, 300 and 400 mL/min
Number of subjects: 22
Study 23656365 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received HIV survey post-test)
Number of subjects: 143
Study 23656365 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (received neutral, non-HIV-related survey pre-test)
Number of subjects: 143
Study 21827531 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention for Alcohol Use
Number of subjects: 95
Study 21827531 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care (Control)
Number of subjects: 95
Study 18783971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg kg(‐1) at induction, 1 mg kg(‐1) h(‐1) during surgery, then 1 mg kg(‐1) during 24 h; n=42)
Number of subjects: 86
Study 18783971 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo; n=44)
Number of subjects: 86
Study 16924687 — intervention group
Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI) in patients with FM
Number of subjects: 30
Study 16924687 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 16924687 — intervention group
Group type: EXPERIMENTAL
Intervention: PSQI component scores in patients with FM
Number of subjects: 30
Study 16924687 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific sleep difficulties in patients with FM
Number of subjects: 30
Study 15272090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy and sertraline
Number of subjects: 858
Study 15272090 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 858
Study 11359393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopiroxolamine 1% cream
Number of subjects: 129
Study 11359393 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 129
Study 9225847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal administration of baclofen
Number of subjects: 1
Study 7967424 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 7967424 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 7967424 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive radiotherapy (CESS 86)
Number of subjects: 0
Study 7967424 — intervention group
Group type: EXPERIMENTAL
Intervention: Early irradiation (CESS 86)
Number of subjects: 0
Study 7967424 — intervention group
Group type: EXPERIMENTAL
Intervention: High quality radiation therapy (CESS 86)
Number of subjects: 0
Study 3191933 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (single infusion)
Number of subjects: 0
Study 3191933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31465791 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine gel
Number of subjects: 18
Study 31465791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intraurethral aqueous gel)
Number of subjects: 18
Study 28616887 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training (CBT only)
Number of subjects: 0
Study 28616887 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based training with homecare worker peer facilitation (CBT + peer)
Number of subjects: 0
Study 28616887 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25646883 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV counseling and testing offered to blood donors (n=6298)
Number of subjects: 11867
Study 25646883 — intervention group
Group type: COMPARATOR
Intervention: Usual procedure (control group, n=5569)
Number of subjects: 11867
Study 25646883 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV counseling and testing offered to blood donors (n=81 who chose testing)
Number of subjects: 11867
Study 23731775 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8mg once daily for 3-6 weeks before ECV and 16mg once daily for 6 months after ECV
Number of subjects: 171
Study 23731775 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3-6 weeks before ECV and placebo for 6 months after ECV
Number of subjects: 171
Study 23731775 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 171
Study 23731775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 23731775 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline YKL‐40 levels
Number of subjects: 171
Study 23731775 — intervention group
Group type: EXPERIMENTAL
Intervention: YKL‐40 levels at end of study
Number of subjects: 171
Study 21613787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day)
Number of subjects: 458
Study 21613787 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg/day)
Number of subjects: 458
Study 21613787 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 458
Study 21613787 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 458
Study 18665413 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 meals/week fatty fish (n = 11)
Number of subjects: 33
Study 18665413 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 meals/week lean fish (n = 12)
Number of subjects: 33
Study 18665413 — intervention group
Group type: COMPARATOR
Intervention: Control diet including lean meat (n = 10)
Number of subjects: 33
Study 16547838 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel instrument for self-quantification of energy expenditure
Number of subjects: 418
Study 15217041 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental [Boredom] group (completed a 15-min. 'boredom' test)
Number of subjects: 56
Study 15217041 — intervention group
Group type: COMPARATOR
Intervention: Control group (participated in relaxing activities)
Number of subjects: 56
Study 11111140 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple vascular risk factors (2 or more)
Number of subjects: 0
Study 8874455 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (45 Gy in twenty or twenty-five fractions over 4-5 weeks)
Number of subjects: 585
Study 8874455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT) with radiotherapy, 5-fluorouracil (1000 mg/m2 for 4 days or 750 mg/m2 for 5 days), and mitomycin (12 mg/m2 on day 1 of the first course)
Number of subjects: 585
Study 8874455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (CMT)
Number of subjects: 585
Study 1531573 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus cefamandole
Number of subjects: 33
Study 1531573 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus doxycycline
Number of subjects: 33
Study 1531573 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic grading of severity
Number of subjects: 33
Study 6401351 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil (250 mg per day)
Number of subjects: 39
Study 6401351 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 31056997 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led group program
Number of subjects: 42
Study 31056997 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 42
Study 27903568 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial delivery of bone marrow CD133+ cells (n=16)
Number of subjects: 31
Study 27903568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 31
Study 26159014 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi benefiting blood activating method (QB-BAM) with Shengmai Injection and Tanshinone IIA Injection
Number of subjects: 60
Study 26159014 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for AECOPD
Number of subjects: 60
Study 25153084 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily protease inhibitor (PI) based regimen (ATV+DDI+FTC)
Number of subjects: 1571